The non-invasive blood glucose level measurement device (1) is provided with a pulse waveform measurement unit (2) having FBG sensors (4) for measuring an acceleration pulse wave of a test subject; and a data-processing unit (3) for calculating the blood glucose level of the test subject at the point in time of measurement of the acceleration pulse wave, from waveform information of the measured acceleration pulse wave, on the basis of a predetermined correlation. The correlation is a calibration curve constructed by carrying out a PLS regression analysis, using the blood glucose level measured by a non-invasive blood glucose method as the objective variable, and a simultaneously-measured acceleration pulse wave as the explanatory variable. A non-invasive blood glucose level measurement device capable of measuring blood glucose level at about the same measurement accuracy as an invasive blood glucose measurement device can be achieved thereby.

A diaper with urine detection functionalities is provided. The diaper includes a urine isolation layer, an absorbent core layer, and an outer layer. A urine detection device is disposed between the urine isolation layer and the absorbent core layer. The isolation layer has an open end that is embedded in a sleeve of the absorbent core layer. The urine detection device comprises a detection circuit and a test paper composite. The test paper composite includes: a trace element test paper, an antibiotic test paper, and a urine routine test paper. Each test paper is made up of a plurality of test strips for detecting different elements. Each test strip produces results according to a different color indicator scheme.

A diaper, having urine detection functionalities, comprises a urine isolation layer, an absorbent core layer and an outer layer. A urine detection device is disposed in between the urine isolation layer and the absorbent core layer. The urine isolation layer has an open end embedded in a sleeve of the absorbent core layer. The urine detection device comprises a detection circuit and a test paper composite. The test paper composite includes: a trace element test paper, an antibiotic test paper and a urine routine test paper. Each test paper is made up of test strips for detecting different elements. Each test strip produces results according to a different color indicator scheme. The antibiotic test paper includes a specimen absorption pad, a specimen binding pad, a reaction membrane, and an absorbent pad. An antibiotic detection method is provided.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and/or lab test data collected for the patient. The platform receives patient data recorded during the current time period comprising food items consumed, medications taken, and symptoms experienced by the patient. The platform implements a machine-learned metabolic model to determine a metabolic state of the patient at a conclusion of the current time period by comparing a true representation of the metabolic state and a prediction of the metabolic state. The true representation and the prediction are determined based on the recorded biosignals and the recorded patient data, respectively. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve their metabolic state and provides the patient-specific treatment recommendation to the patient device for display to the patient.

Systems, devices and methods are provided for power-efficient wireless communications between electronic devices. In particular, the embodiments disclosed herein can reduce battery consumption in a transmitting electronic device and enhance data integrity of data received by a receiving electronic device. According to the embodiments, a first electronic device transmits advertising packets according to a wireless communications protocol, wherein the advertising packets include a first payload data. In response to receiving the advertising packets, a second electronic device can transmit a scan request to the first electronic device which, in turn, terminates the transmission of advertising packets.

Physiological signal processing systems include a photoplethysmograph (PPG) sensor that is configured to generate a physiological waveform, and an inertial sensor that is configured to generate a motion signal. A physiological metric extractor is configured to extract a physiological metric from the physiological waveform that is generated by the PPG sensor. The physiological metric extractor includes an averager that has an impulse response that is responsive to the strength of the motion signal. Related methods are also described.

The present disclosure relates to methods and systems suitable for use in identifying and providing personalised medicine to a patient. In some aspects, systems and method generate a co-therapy regimen for a patient suffering from a disease or condition. An identification of a co-therapy suitable to treat the disease or condition is received. A desired patient endpoint and a patient position are received, wherein the patient position is defined relative to the desired patient endpoint. A dataset relating to the patient is stored. The dataset comprises one or more patient data based on patient-related measurements. The dataset, the patient position and the desired patient endpoint are processed to generate a regimen for the co-therapy. The regimen is stored in a database.

A physiological sensor has light emitting sources, each activated by addressing at least one row and at least one column of an electrical grid. The light emitting sources are capable of transmitting light of multiple wavelengths and a detector is responsive to the transmitted light after attenuation by body tissue.

Methods and devices to monitor an analyte in body fluid are provided. Embodiments include continuous or discrete acquisition of analyte related data from a transcutaneously positioned in vivo analyte sensor automatically or upon request from a user. The in vivo analyte sensor is coupled to an electronics unit holding a memory with instruction to cause processing circuitry to initiate a predetermined time period that is longer than a predetermined life of the sensor, during the predetermined time period, convert signals from the sensor related to glucose to respective corresponding glucose levels, without relying on any post-manufacture independent analyte measurements from a reference device, and at the expiration of the predetermined time period, disable, deactivate, or cease use of one or more feature.

Methods, apparatuses, and systems are provided for determining whether to administer a medication dose as a single dose or whether to fractionate the single dose to be administered as at least two discrete doses. Embodiments include determining a first analyte level and a first rate of change of the analyte level; determining an initial medication dose based on one or more anticipated subsequent medication doses, the first analyte level relative to an analyte level threshold, and the first rate of change of the analyte level relative to a rate of change threshold; administering the initial medication dose; determining a second analyte level and a second rate of change of the analyte level based on subsequent analyte data; and determining a subsequent medication dose based on the second analyte level relative to the analyte level threshold and the second rate of change relative to the rate of change threshold.